Savara Dirección
Dirección controles de criterios 3/4
El CEO de Savara's es Matt Pauls , nombrado en Sep 2020, tiene una permanencia de 3.75 años. compensación anual total es $3.76M, compuesta por 15.8% salario y 84.2% primas, incluidas acciones y opciones de la empresa. posee directamente un 0.37% de las acciones de la empresa, por valor de $2.07M. La antigüedad media del equipo directivo y de la junta directiva es de 2.8 años y 7.2 años, respectivamente.
Información clave
Matt Pauls
Chief Executive Officer (CEO)
US$3.8m
Compensación total
| Porcentaje del salario del CEO | 15.8% |
| Permanencia del CEO | 4yrs |
| Participación del CEO | 0.3% |
| Permanencia media de la dirección | 3yrs |
| Promedio de permanencia en la Junta Directiva | 7.4yrs |
Actualizaciones recientes de la dirección
Recent updates
Savara: Trial Successful, But I'm Only Half Convinced
Sep 09Savara: Today's Data 'Win' Rouses Market All Too Briefly
Jun 26Savara: The Binary Bet On Phase 3 Data
Jun 07Health Check: How Prudently Does Savara (NASDAQ:SVRA) Use Debt?
Dec 14
Is Savara (NASDAQ:SVRA) Using Too Much Debt?
Feb 16Is Savara (NASDAQ:SVRA) Using Too Much Debt?
Oct 12Savara's rare lung disorder drug gets promising innovative medicine status in UK
Aug 26Savara GAAP EPS of -$0.06 in-line
Aug 11Does Savara (NASDAQ:SVRA) Have A Healthy Balance Sheet?
Jan 24Is Savara (NASDAQ:SVRA) A Risky Investment?
Jul 05Savara: They Failed Once, But They Are Trying Again
Jun 07The Independent Director of Savara Inc. (NASDAQ:SVRA), David Ramsay, Just Bought 565% More Shares
Mar 17Trade Alert: The Chairman & CEO Of Savara Inc. (NASDAQ:SVRA), Matthew Pauls, Has Just Spent US$50k Buying 4,415% More Shares
Feb 26Savara's IMPALA 2 Trial Seems Well-Tailored To Get Positive Phase 3 Data For Molgradex
Nov 24Savara EPS misses by $0.01
Nov 05Análisis de compensación del CEO
| Fecha | Compensación total | Salario | Ingresos de la empresa |
|---|---|---|---|
| Jun 30 2024 | n/a | n/a | -US$75m |
| Mar 31 2024 | n/a | n/a | -US$64m |
| Dec 31 2023 | US$4m | US$595k | -US$55m |
| Sep 30 2023 | n/a | n/a | -US$49m |
| Jun 30 2023 | n/a | n/a | -US$43m |
| Mar 31 2023 | n/a | n/a | -US$40m |
| Dec 31 2022 | US$2m | US$580k | -US$38m |
| Sep 30 2022 | n/a | n/a | -US$39m |
| Jun 30 2022 | n/a | n/a | -US$39m |
| Mar 31 2022 | n/a | n/a | -US$41m |
| Dec 31 2021 | US$2m | US$560k | -US$43m |
| Sep 30 2021 | n/a | n/a | -US$45m |
| Jun 30 2021 | n/a | n/a | -US$46m |
| Mar 31 2021 | n/a | n/a | -US$44m |
| Dec 31 2020 | US$2m | US$170k | -US$50m |
| Sep 30 2020 | n/a | n/a | -US$68m |
| Jun 30 2020 | n/a | n/a | -US$69m |
| Mar 31 2020 | n/a | n/a | -US$81m |
| Dec 31 2019 | US$64k | n/a | -US$78m |
| Sep 30 2019 | n/a | n/a | -US$57m |
| Jun 30 2019 | n/a | n/a | -US$57m |
| Mar 31 2019 | n/a | n/a | -US$47m |
| Dec 31 2018 | US$114k | n/a | -US$62m |
| Sep 30 2018 | n/a | n/a | -US$58m |
| Jun 30 2018 | n/a | n/a | -US$52m |
| Mar 31 2018 | n/a | n/a | -US$53m |
| Dec 31 2017 | US$75k | n/a | -US$31m |
Compensación vs. Mercado: La compensación total ($USD3.76M) de Matt está en línea con el promedio de empresas de tamaño similar en el mercado US ($USD3.41M).
Compensación vs. Ingresos: La compensación de Matt ha aumentado mientras la empresa no es rentable.
CEO
Matt Pauls (53 yo)
4yrs
Permanencia
US$3,759,723
Compensación
Mr. Matthew Pauls, J.D. M.B.A. also known as Matt, is Director at NVN Liquidation Inc. He serves as Director of Soleno Therapeutics, Inc. since August 15, 2023 and is its Lead Independent Director aince Au...
Equipo directivo
| Nombre | Posición | Permanencia | Compensación | Propiedad |
|---|---|---|---|---|
| Chairman & CEO | 4yrs | US$3.76m | 0.31% $ 2.2m | |
| CFO, Chief Administrative Officer & Secretary | 7.8yrs | US$1.52m | 0.050% $ 349.2k | |
| Chief Operating Officer | 1.6yrs | US$2.66m | 0% $ 0 | |
| Senior VP & General Counsel | 6.5yrs | sin datos | sin datos | |
| Chief Business Officer | 3.9yrs | sin datos | 0.071% $ 495.0k | |
| Head of Clinical Operations | 3.3yrs | sin datos | sin datos | |
| Senior Vice President of Global Regulatory Affairs & Quality Assurance | 3.1yrs | sin datos | sin datos | |
| Executive Vice President of Global Technical Operations | 3yrs | sin datos | sin datos | |
| Chief Medical Officer | 1.8yrs | US$698.69k | 0.0061% $ 42.4k | |
| Executive Vice President of Global Commercial | 1.7yrs | sin datos | sin datos | |
| Senior VP of Global Medical Affairs | 1.4yrs | sin datos | sin datos | |
| Executive VP and Head of Clinical Development & Clinical Operations | less than a year | sin datos | sin datos |
3.0yrs
Permanencia media
56yo
Promedio de edad
Equipo directivo experimentado: El equipo directivo de SVRA se considera experimentado (2.8 años antigüedad media).
Miembros de la Junta
| Nombre | Posición | Permanencia | Compensación | Propiedad |
|---|---|---|---|---|
| Chairman & CEO | 7.4yrs | US$3.76m | 0.31% $ 2.2m | |
| Independent Director | 7.4yrs | US$158.13k | 1.34% $ 9.3m | |
| Lead Independent Director | 10.9yrs | US$155.13k | 0.10% $ 713.7k | |
| Independent Director | 13.9yrs | US$149.13k | 0.0077% $ 54.0k | |
| Independent Director | 15.6yrs | US$157.63k | 0% $ 0 | |
| Member of Clinical Advisory Board | no data | sin datos | sin datos | |
| Member of Clinical Advisory Board | no data | sin datos | sin datos | |
| Member of Clinical Advisory Board | no data | sin datos | sin datos | |
| Independent Director | 4.8yrs | US$155.63k | 0% $ 0 | |
| Member of Clinical Advisory Board | 3.7yrs | sin datos | sin datos | |
| Member of Clinical advisory Board | 1.7yrs | sin datos | sin datos |
7.4yrs
Permanencia media
61.5yo
Promedio de edad
Junta con experiencia: La junta directiva de SVRA se considera experimentada (7.2 años de antigüedad promedio).